Results 81 to 90 of about 8,834,434 (252)

Metabolic Dysfunction‐Associated Steatotic Liver Disease and Obesity: Pathogenesis, Diagnostics, Risk Stratification, and Therapeutic Approach

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Metabolic dysfunction‐associated steatotic liver disease (MASLD) has emerged as the most prevalent chronic liver disease worldwide, closely linked to the global rising incidence of obesity and metabolic syndrome. This review synthesizes current evidence on the pathogenesis, gut–liver axis, and multidisciplinary management of MASLD within the ...
Beom Kyung Kim
wiley   +1 more source

Use of microdoses for induction of buprenorphine treatment with overlapping full opioid agonist use: the Bernese method [PDF]

, 2016
BACKGROUND: Buprenorphine is a partial µ-opioid receptor agonist used for maintenance treatment of opioid dependence. Because of the partial agonism and high receptor affinity, it may precipitate withdrawal symptoms during induction in persons on full µ ...
Hämmig, Robert, Gugger, Barbara, Walter, Marc, Vogel, Marc, Dürsteler, Kenneth, von Bardeleben, Ulrich, Kemter, Antje, Strasser, Johannes, von Bardeleben U, Walter M, Kemter A, Strasser J, Gugger B, Dürsteler KM, Hämmig R, Vogel M   +15 more
core   +1 more source

Challenges of Pain in Parkinson's Disease: Results from the OCEAN Study

Movement Disorders, EarlyView.
Abstract Background Pain is a common non‐motor symptom in Parkinson’s disease (PD) and is often associated to fluctuations. Objective The OpiCapone Effect on motor fluctuations and pAiN (OCEAN) study evaluated the effect of opicapone on fluctuation‐related pain when added to levodopa therapy in PD patients.
Kallol Ray Chaudhuri, Joaquim J. Ferreira, Angelo Antonini, Olivier Rascol, Monica M. Kurtis, Alexander Storch, José‐Francisco Rocha, Raquel Costa, Diogo Magalhães, Guillermo Castilla‐Fernández, Helena C. Brigas, Joerg Holenz, Per Odin, on behalf of the OCEAN study group   +13 more
wiley   +1 more source

A Narrative Pharmacological Review of Buprenorphine: A Unique Opioid for the Treatment of Chronic Pain

Pain and Therapy, 2020
Buprenorphine is a Schedule III opioid analgesic with unique pharmacodynamic and pharmacokinetic properties that may be preferable to those of Schedule II full μ-opioid receptor agonists.
Jeffrey Gudin, Jeffrey Fudin
doaj   +1 more source

Cross‐Cohort Evidence Links KCNJ6 rs702859 to Impulsive–Compulsive Phenotypes in Parkinson's Disease

Movement Disorders, EarlyView.
Abstract Background Impulse control disorders (ICDs) and related compulsive behaviors (CBs) are frequent non‐motor complications of Parkinson's disease (PD) with a probable genetic contribution. Objective To investigate whether genetic variants involved in reward and punishment processing are associated with impulsive–compulsive phenotypes in PD ...
Sergio García‐Díaz, Juan Francisco Martín‐Rodríguez, Laura Muñoz‐Delgado, Rafael Díaz‐Belloso, Silvia Jesús, María Teresa Periñán, Miguel Martín‐Bórnez, Ana M. Castellano‐Guerrero, Elena Ojeda‐Lepe, Daniel Macías‐García, Astrid Adarmes‐Gómez, Dolores Buiza‐Rueda, Marta Bonilla‐Toribio, Elena Iglesias‐Camacho, Manuela San‐Eufrasio, Cristina Pérez‐Calvo, Rocío Pineda‐Sánchez, Francisco Javier Gómez‐Campos, Antonio Luque‐Ambrosiani, Fátima Carrillo‐García, Pilar Gómez‐Garre, Pablo Mir   +21 more
wiley   +1 more source

The opioid crisis: past, present and future policy climate in Ontario, Canada

Substance Abuse Treatment, Prevention, and Policy, 2017
Background Addressing opioid use disorder has become a priority in Ontario, Canada, because of its high economic, social and health burden. There continues to be stigma and criticism relating to opioid use disorder and treatment options.
Kristen A. Morin, Joseph K. Eibl, Alexandra M. Franklyn, David C. Marsh   +3 more
doaj   +1 more source

Developing the Dopamine D3 Receptor (D3R) Antagonist, (R)‐VK4‐116, as a Non‐Opioid Medication for the Treatment of Opioid Use Disorder

Medicinal Research Reviews, EarlyView.
ABSTRACT Opioid use disorder (OUD) remains a major global health challenge, and currently approved treatments (methadone, buprenorphine, and naltrexone) are all opioid receptor‐targeting drugs with limitations in access, adherence, stigma, and use in polysubstance use disorders. Because the dopamine D3 receptor (D3R) is enriched in limbic brain regions
Chia‐Kuei Wu, Yu‐Chih Lin, Junfeng Huang, Bangwei Ding, Pramod Terse, Rahul Nandre, Haksong Jin, Molly Congdon, Kun Shen, Philip Sanderson, Gregory Tawa, Stephanie Mounaud, Marta De Santis, Donald Lo, Elizabeth A. Ottinger, Amy Hauck Newman   +15 more
wiley   +1 more source

Repurposing antimicrobial agents for neuroprotection: Mechanisms, clinical potential, and challenges

Neuroprotection, EarlyView.
Antimicrobial agents exert neuroprotective effects through modulation of interconnected pathways. Tetracyclines, macrolides, antimalarial agents, sulfones, and antiparasitic agents suppress neuroinflammation, oxidative stress, and apoptosis while preserving mitochondrial function and neurotransmission.
Mohammad Amin Manavi, Mohammadreza Salehi, Razieh Mohammad Jafari, Ramin Goudarzi, Saman Khosravi, Ahmad Reza Dehpour   +5 more
wiley   +1 more source

Pharmacological enhancement of naltrexone treatment for opioid dependence: a review

Substance Abuse and Rehabilitation, 2011
Paolo Mannelli, Kathleen S Peindl, Li-Tzy WuDepartment of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC, USAPurpose: Opioid dependence (OD) is a serious and growing clinical condition with increasing social costs that ...
Peindl K, Mannelli P, Wu LT
doaj  

Integrated exercise program in opioid agonist therapy clinics and effect on psychological distress: study protocol for a randomized controlled trial (BAReAktiv)

Trials
Background Substance use disorder is associated with unhealthy lifestyle choices, resulting in adverse social and health consequences. People with opioid use disorder receiving opioid agonist therapy, in particular, have high morbidity and reduced ...
Einar Furulund, Tesfaye Madebo, Karl Trygve Druckrey-Fiskaaen, Jørn Henrik Vold, Mette Hegland Nordbotn, Eivin Dahl, Sindre M. Dyrstad, Torgeir Gilje Lid, Lars T. Fadnes, for the ATLAS4LAR study group   +9 more
doaj   +1 more source